Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE
January 14, 2021
DEER PARK, Ill. , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE
Read More
Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution
December 17, 2020
Application Assigned a PDUFA Date of August 6, 2021 DEER PARK, Ill. , Dec. 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the U.S.
Read More
Eton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States
November 24, 2020
ALKINDI ® SPRINKLE is now exclusively available through AnovoRx Specialty Pharmacy . To support patient access to ALKINDI ® SPRINKLE, Eton has established the Eton Cares Program ® . DEER PARK, Ill. , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty
Read More
Email Alerts

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.